<div id="readability-page-1"><div><h2>Clinical trial approval and what it means for investors</h2> <p>United Laboratories International Holdings (SEHK:3933) has drawn fresh attention after regulators in China approved the clinical trial application for its dupilumab biosimilar targeting atopic dermatitis, a step that highlights progress in its autoimmune pipeline.</p> <p>See our latest analysis for United Laboratories International Holdings.</p> <p>The share price has recently picked up, with a 1-day share price return of 2.77% taking the stock to HK$9.65. However, that comes after a 30-day share price return of an 8.44% decline and a 90-day share price return of a 23.59% decline. At the same time, the 3-year total shareholder return of 68.18% and 5-year total shareholder return of 81.99% point to a very different longer term picture. Overall, momentum currently looks to be fading despite the latest clinical trial approval.</p> <p>If this kind of healthcare catalyst has your attention, it can be useful to compare with other life sciences opportunities via a focused screener such as 124 healthcare AI stocks</p> <p>So, with clinical progress in autoimmune diseases, solid recent revenue and net income figures, and a sizeable discount to the current analyst price target, is United Laboratories undervalued, or is the market already pricing in its future growth?</p> <h2>Price to earnings of 7.9x: Is it justified?</h2> <p>On simple valuation checks, United Laboratories looks inexpensive, with a P/E of 7.9x at a last close of HK$9.65 and several models pointing to a discount versus both peers and internal fair value estimates.</p> <p>The P/E multiple compares the share price to earnings per share and is a common way investors weigh what they are paying for each unit of profit. For a profitable pharmaceutical group with HK$13,210.63m in revenue and HK$2,085.90m in net income, this is a key reference point when you think about how the market is pricing its earnings power.</p> <p>Right now, the stock trades at a P/E of 7.9x versus a peer average of 25.3x and a Hong Kong pharmaceuticals industry average of 14.2x, while the SWS fair P/E ratio is estimated at 18.2x. That is a wide gap. If the market moves closer to that fair ratio over time, it would imply a very different valuation profile to today.</p> <p>Explore the SWS fair ratio for United Laboratories International Holdings</p> <p>On top of that, the SWS DCF model estimates a future cash flow value of HK$26.11 per share compared with the current HK$9.65. This indicates a strong underpricing signal if those cash flow assumptions play out. The DCF works by projecting the cash the company is expected to generate in future years and discounting it back to today at an appropriate rate, which is a useful cross check alongside earnings based metrics.</p> <p>Look into how the SWS DCF model arrives at its fair value.</p> <p><strong>Result: Price to earnings of 7.9x (UNDERVALUED).</strong></p> <p>However, there are still clear risks, including clinical setbacks in the autoimmune pipeline and pricing or competitive pressure across key bulk and finished product segments.</p> <p>Find out about the key risks to this United Laboratories International Holdings narrative.</p> <h2>Another view: what if the market is right to be cautious?</h2> <p>Those valuation checks look attractive, but the recent picture is more mixed. Net profit margins have eased from 19.3% to 15.8%, with a 21.6% earnings decline over the past year, and a 1 year total return of 24.74% while both the Hong Kong market and pharmaceuticals industry moved higher. With earnings forecast to grow 7.5% per year, slower than market expectations, how much weight should you really put on the apparent discount?</p> <p>Look into how the SWS DCF model arrives at its fair value.</p> <figure><img height="476" src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/a97bc5e5-972b-4478-b834-7b23e295ac97/chart/dcf/query-ZGF0ZT0yMDI2LTA1LTA2?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="746" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/a97bc5e5-972b-4478-b834-7b23e295ac97/chart/dcf/query-ZGF0ZT0yMDI2LTA1LTA2"/><figcaption>3933 Discounted Cash Flow as at May 2026</figcaption></figure><p>Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out United Laboratories International Holdings for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 225 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.</p> <h2>Next Steps</h2> <p>With mixed signals across valuation, earnings and recent returns, the next move is not obvious. It makes sense to look at the full picture yourself, weigh both the concerns and the potential, and check the 4 key rewards and 1 important warning sign</p> <h2>Looking for more investment ideas?</h2> <p>If you leave it here, you risk missing out on other stocks that might fit your goals even better, so use this momentum to broaden your watchlist.</p> <ul> <li>Spot potential upside early by scanning screener containing 546 high quality undiscovered gems and see which under-the-radar stocks line up with your preferred fundamentals.</li> <li>Strengthen your downside protection by reviewing 307 resilient stocks with low risk scores and focus on companies with resilience at the core of their profiles.</li> <li>Target quality at a discount by checking 225 high quality undervalued stocks and compare how other stocks stack up against your return expectations.</li> </ul> <p><em> This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data         and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your         financial situation. We aim to bring you long-term focused analysis driven by fundamental data.         Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.         Simply Wall St has no position in any stocks mentioned.</em></p><div><h3><strong>New: </strong>AI Stock Screener &amp; Alerts</h3><p>Our new AI Stock Screener scans the market every day to uncover opportunities.</p><div><p>• Dividend Powerhouses (3%+ Yield)<br/>• Undervalued Small Caps with Insider Buying<br/>• High growth Tech and AI Companies</p><p>Or build your own from over 50 metrics.</p></div><p>Explore Now for Free</p></div></div></div>

03933

<p>United Laboratories International Holdings (SEHK:3933) received approval for a clinical trial of its dupilumab biosimilar, boosting investor interest. The stock rose 2.77% to HK$9.65, despite a recent decline of 8.44% over 30 days. With a P/E ratio of 7.9x, significantly lower than industry peers, the stock appears undervalued. However, risks include potential clinical setbacks and competitive pressures. While earnings are forecasted to grow at 7.5% annually, recent profit margins have decreased, raising questions about the sustainability of the current valuation.</p>

Assessing United Laboratories International Holdings (SEHK:3933) Valuation After Dupilumab Biosimilar Trial Approval